Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STRIPe: Molecularly Matched Therapy vs Standard of Care in Metastatic Solid Cancers
NCT07346209Phase 2Not yet recruiting
- Sponsor
- University of California, San Diego
- Start
- Dec 2026
- Primary completion
- Mar 2031
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in metastatic cancer and carcinoma (2 arms), sponsored by University of California, San Diego. Primary endpoint: Progression-Free Survival at 1 year. Planned start Dec 2026; status: not yet recruiting.
02
Conditions
metastatic cancercarcinoma
Beyond the preview
Go deeper on NCT07346209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07346209.